SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
出版年份 2018 全文链接
标题
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
作者
关键词
-
出版物
NATURE MEDICINE
Volume 24, Issue 4, Pages 512-517
出版商
Springer Nature
发表日期
2018-03-06
DOI
10.1038/nm.4497
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
- (2015) Gorjan Hrustanovic et al. NATURE MEDICINE
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
- (2013) Soyeon Kim et al. Journal of Thoracic Oncology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Treating ALK-positive lung cancer—early successes and future challenges
- (2012) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now